Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 299 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Lesions Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lesion Detection of Automated Breast Ultrasound Compared With Handheld Physician-performed Breast Ultrasound

NCT02310776
View directory record Official record
Conditions
Breast Diseases
Interventions
Supine automated breast ultrasound scanner, High-resolution handheld breast ultrasound
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
501 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 24, 2026, 7:32 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Iontophoresis in Psoriasis

NCT03979664
View directory record Official record
Conditions
Psoriasis, Psoriasis Vulgaris, Skin Diseases
Interventions
Activapatch intellidose 2.5 using active Iontophoresis, Activapatch intellidose 2.5 using inactive Iontophoresis, Dexamethasone
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 24, 2026, 7:32 AM EDT
Not listed Phase 2 Interventional

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

NCT04759664
View directory record Official record
Conditions
EGFRI Induced Acneiform Lesions
Interventions
LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Glendale, California • Santa Monica, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 24, 2026, 7:32 AM EDT
Terminated Phase 2 Interventional Results available

Spesolimab in Pyoderma Gangrenosum

NCT06092216
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
Spesolimab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Foam Tape Allergy a Sticky Situation

NCT06059417
View directory record Official record
Conditions
Medical Adhesive Allergy, Dermatologic Conditions, Dermatologic Lesions
Interventions
2x2 inch piece of 3M microfoam adhesive
Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Results available

Symptom Management After Breast Cancer Surgery

NCT00686127
View directory record Official record
Conditions
Neuropathic Pain, Postmastectomy Pain
Interventions
Lidoderm patch, Placebo patch
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 24, 2026, 7:32 AM EDT
Withdrawn Not applicable Interventional

Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses

NCT00814528
View directory record Official record
Conditions
Actinic Keratosis
Interventions
5-ALA plus Blu-Light, 5-FU, Imiquimod or treatment with cryotherapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 24, 2026, 7:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of Noninvasive Methods to Evaluate Skin and Mucosal Conditions

NCT04743362
View directory record Official record
Conditions
Skin Lesion, Mucosal Lesion
Interventions
Dermoscopic imaging, 3-dimensional total body photography, Confocal microscopy, Optical Coherence Tomography imaging, Ultrasound, Hyperspectral imaging, Electrical impedance spectroscopy, Patient self-imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
5,010 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin

NCT04059588
View directory record Official record
Conditions
Cancer, Solid Tumor, Cancer of Skin
Interventions
2141 V-11
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Can We Miss Pigmented Lesions in Psoriasis Patients?

NCT01053819
View directory record Official record
Conditions
Psoriasis, Melanoma, Non-melanoma Skin Cancer
Interventions
etanercept
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

NCT01849250
View directory record Official record
Conditions
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Docosahexaenoic Acid, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon

NCT02737618
View directory record Official record
Conditions
Dermal Irritation
Interventions
Trojan "Chameleon" Personal Lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Pigmented Skin Lesions With MelaFind(R) System

NCT00434057
View directory record Official record
Conditions
Melanoma
Interventions
MelaFind(R)
Device
Lead sponsor
MELA Sciences, Inc.
Industry
Eligibility
Not listed
Enrollment
1,383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Plantation, Florida • Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

NCT03714828
View directory record Official record
Conditions
Squamous Cell Carcinoma, Skin Cancer, Keratoacanthoma, Cutaneous Tumor, Skin Cancer, Squamous Cell, Lesion Skin
Interventions
Injection of TVEC into target lesions - week 1-2, Injection of TVEC into target lesions 3wks after 1st injection, Injection of TVEC into target lesions 2wks after 2nd injection, Injection of TVEC into target lesions 2wks after 3rd injection
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects

NCT01681745
View directory record Official record
Conditions
Histological Response of Tissue to Cold
Interventions
Cryo-Touch III
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 24, 2026, 7:32 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274
View directory record Official record
Conditions
Skin Irritation
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 24, 2026, 7:32 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Wearable Ultrasound Patch for Breast Imaging

NCT07186491
View directory record Official record
Conditions
Breast Cancer, Breast Abnormalities, Breast Lesion, Breast Asymmetry
Interventions
Wearable Ultrasound Patch
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 24, 2026, 7:32 AM EDT
Not yet recruiting Early Phase 1 Interventional

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

NCT05728879
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma
Interventions
APR-TD011 (RLF-TD011)
Combination Product
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 24, 2026, 7:32 AM EDT
Terminated Early Phase 1 Interventional

Comparison of CE-DBT and MRI in Patients With Known Breast Lesions

NCT05754749
View directory record Official record
Conditions
Breast Cancer
Interventions
Iohexol 350 Mg/mL Injectable Solution
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Not applicable Interventional Results available

Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia

NCT03612570
View directory record Official record
Conditions
Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia
Interventions
Nano-Pulse Stimulation Device
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Sacramento, California • San Mateo, California • Chestnut Hill, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

NCT01537042
View directory record Official record
Conditions
Restless Legs Syndrome, End-Stage Renal Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Brandon, Florida • Newton, Massachusetts • West Seneca, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 24, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer

NCT01187485
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androderm® 2.5mg, Androderm® 5.0mg, Androderm® 7.5mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 24, 2026, 7:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

NCT07201376
View directory record Official record
Conditions
Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth
Interventions
Ameluz 10% Topical Gel, Protoporphyrin IX
Drug · Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 24, 2026, 7:32 AM EDT
Completed No phase listed Observational

Melanoma Detection by Oblique-Incidence Optical Spectroscopy

NCT00526032
View directory record Official record
Conditions
Skin Cancer
Interventions
OIR Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 24, 2026, 7:32 AM EDT